You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

394 Results
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's Low Grade
Intent: Palliative
Funding:
New Drug Funding Program
    Rituximab (Biosimilar IV) and Rituximab SC in Combination with Chemotherapy - Indolent B-cell Lymphoma
New Drug Funding Program
    Rituximab (Biosimilar IV) and Rituximab SC - Retreatment - Indolent Lymphoma
New Drug Funding Program
    Rituximab (Biosimilar IV) and Rituximab SC - Retreatment - Indolent Lymphoma
New Drug Funding Program
    Rituximab (Biosimilar IV) and Rituximab SC in Combination with Chemotherapy - Indolent B-cell Lymphoma
Jun 2021
Regimen
Intent: Palliative
Funding:
ODB - General Benefit
    fulvestrant
Feb 2024
Regimen
Intent: Palliative
Funding:
ODB - General Benefit
    tamoxifen
May 2022
Regimen
Cancer Type:
Hematologic, 
Multiple Myeloma
Intent: Palliative
Jun 2019
Regimen
Cancer Type:
Gastrointestinal, 
Pancreas
Intent: Adjuvant, Palliative
Apr 2023
Regimen
Cancer Type:
Gastrointestinal, 
Esophagus, 
Gastric / Stomach
Intent: Adjuvant, Adjuvant
Nov 2017
Regimen
Cancer Type:
Gastrointestinal, 
Anus
Intent: Adjuvant
Apr 2023
Regimen
Intent: Adjuvant
Funding:
ODB - General Benefit
    tamoxifen
Jun 2022
Regimen
Cancer Type:
Central Nervous System
Intent: Palliative
Funding:
ODB - General Benefit
    temozolomide
Jun 2021
Regimen
Cancer Type:
Central Nervous System
Intent: Adjuvant, Palliative
Funding:
ODB - General Benefit
    temozolomide
Jun 2021
Regimen
Cancer Type:
Gynecologic, 
Ovary
Intent: Palliative
Aug 2021
Regimen
Cancer Type:
Lung, 
Small Cell
Intent: Palliative
Nov 2023

Pages